Test Details
Methodology
Electrophoresis
Result Turnaround Time
3 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Test Includes
Relative percentages of liver, bone and intestinal alkaline phosphatase isoenzymes and total alkaline phosphatase
Use
This test is used to evaluate the contribution of the isoforms of ALP from liver, bone and bowel to total ALP and investigate elevations of ALP to determine the tissue of origin.
Special Instructions
State patient's age and sex on the test request form.
Custom Additional Information
Alkaline phosphatase (ALP) is present in a number of tissues including liver, bone, intestine and placenta.1,2 The activity of ALP found in serum is a composite of isoenzymes from those sites and in some circumstances, placental or Regan isoenzymes. Serum ALP is of interest in the diagnosis of two main groups of conditions: hepatobiliary disease and bone disease associated with increased osteoblastic activity. A rise in ALP activity occurs with all forms of cholestasis, particularly with obstructive jaundice. The response of the liver to any form of biliary tree obstruction is to synthesize more ALP. The main site of new enzyme synthesis is the hepatocytes adjacent to the biliary canaliculi. ALP is also elevated in disorders of the skeletal system that involve osteoblast hyperactivity and bone remodeling, such as Paget disease, rickets, osteomalacia, fractures and malignant tumors. Moderate elevation of ALP may be seen in other disorders such as Hodgkin disease, congestive heart failure, ulcerative colitis, regional enteritis and intra-abdominal bacterial infections.
Liver is the isoenzyme most frequently elevated when total ALP levels are elevated. Liver ALP increases in the blood early in liver disease before most other liver function tests show abnormalities. The wide group of conditions leading to increased liver ALP include acute hepatitis, cirrhosis, fatty liver, drug-induced liver disease, obstruction of biliary flow by carcinoma at the head of the pancreas, bile duct stricture, primary biliary cirrhosis and metastatic carcinoma of the liver.
Bone isoenzyme is elevated as a result of increased osteoblastic activity. This isoenzyme is normally elevated in growing children and adults above age 50. The highest total ALP values have been attributed to an increased bone isoenzyme level due to Paget disease or renal rickets. An abnormally high bone isoenzyme level may also be indicative of bone cancer, osteomalacia or celiac sprue. A decreased bone ALP in children may be attributed to cretinism or to hypophosphatasia.
Intestinal alkaline phosphatase is seen normally in the serum of subjects who have B or O blood types, especially after a fatty meal. Pathologically, the band may be present in perforation of the bowel, ulcerative disease of the intestine and faintly in liver cirrhosis. Acute infarction of the intestine will cause a release of intestinal ALP from the mucosa. Large erosive or ulcerative lesions of the stomach, duodenum or other small intestinal areas or colon may result in an elevation of the serum ALP level. The small intestinal lesions associated with malabsorption are associated with an elevation of the serum intestinal ALP level only if there is an erosive or ulcerative mucosal lesion.
Specimen Requirements
Specimen
Serum or plasma (lithium-heparin)
Volume
1.6 mL
Minimum Volume
0.8 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube, gel-barrier tube or green-top (lithium-heparin) tube
Collection Instructions
Serum: Separate serum from cells as soon as possible after the blood is allowed to clot.
Plasma: Centrifuge and transfer separated heparin plasma to a plastic transport tube and label as Li-heparin plasma.
Stability Requirements
| Temperature | Period |
| Room temperature | 7 days |
| Refrigerate | 7 days |
| Frozen | 3 months |
| Freeze/thaw cycles | Stable x3 |
Reference Range
| Alkaline Phosphatase (IU/L) | ||
| Age | Male | Female |
| 0 to 5 d | 47–127 | 47–127 |
| 6 to 10 d | 29–242 | 29–242 |
| 11 to 20 d | 109–357 | 109–357 |
| 21 to 30 d | 94–494 | 94–494 |
| 1 to 2 m | 149–539 | 149–539 |
| 3 to 6 m | 131–452 | 131–452 |
| 7 to 11 m | 117–401 | 117–401 |
| 12 m to 6 y | 158–369 | 158–369 |
| 7 to 12 y | 150–409 | 150–409 |
| 13 y | 156–435 | 78–227 |
| 14 y | 114–375 | 64–161 |
| 15 y | 88–279 | 56–134 |
| 16 y | 74–207 | 51–121 |
| 17 y | 63–161 | 47–113 |
| 18 - 20 y | 51–125 | 42–106 |
| >20 y | 44–121 | 44–121 |
| Liver Fraction (IU/L) | ||
| Age | Male | Female |
| 0 to 6 m | 7–50 | 7–50 |
| 7 m to 5 y | 21–77 | 22–72 |
| 6 to 12 y | 21–62 | 20–57 |
| 13 to 17 y | 16–52 | 18–55 |
| 18 to 100 y | 21–86 | 23–85 |
| Bone Fraction (IU/L) | ||
| Age | Male | Female |
| 0 to 6 m | 24–472 | 24–472 |
| 7 m to 5 y | 129–82 | 126–281 |
| 6 to 12 y | 135–356 | 135–349 |
| 13 to 17 y | 81–323 | 26–75 |
| 18 to 100 y | 16–52 | 18–57 |
| Intestinal Fraction (IU/L) | ||
| Age | Male | Female |
| 0 to 6 m | 0–24 | 0–24 |
| 7 m to 5 y | 0–19 | 0–18 |
| 6 to 12 y | 0–20 | 0–20 |
| 13 to 17 y | 0–19 | 0–18 |
| 18 to 100 y | 0–14 | 0–14 |
Storage Instructions
Refrigerate at 2°C to 8°C as soon as possible after collection.
Causes for Rejection
Patient not fasting; citrate, oxalate or EDTA anticoagulated plasma
References
Cannalire G, Pilloni S, Esposito S, Biasucci G, Di Franco A, Street ME. Alkaline phosphatase in clinical practice in childhood: Focus on rickets. Front Endocrinol (Lausanne). 2023 Feb 2;14:1111445. PubMed 36817604
Coleman R, Brown J, Terpos E, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov;34(7):629-639. PubMed 18579314
Fernández-Gordón Sánchez FM, Labrador CG, Mínguez DR, Fernández SA, Milla CC. Persistently elevated alkaline phosphatase without hepatopathy? Literature review. Rev Esp Enferm Dig. 2024 Aug;116(8):447-448. PubMed 37882192
Jassam NJ, Horner J, Marzo-Ortega H, Sinclair M, Barth JH. Transient rise in alkaline phosphatase activity in adults. BMJ Case Rep. 2009:2009:bcr09.2009.2250. PubMed 22140406
Ramasamy I. Persistent Increase in Serum Alkaline Phosphatase in a Patient with Monoclonal Gammopathy of Undefined Significance. Case Rep Hematol. 2020 Jan 31;2020:8406971. PubMed 32082656
Teitelbaum JE, Laskowski A, Barrows FP. Benign transient hyperphosphatasemia in infants and children: a prospective cohort. J Pediatr Endocrinol Metab. 2011;24(5-6):351-353. PubMed 21823535
Verma J, Gorard DA. Persistently elevated alkaline phosphatase. BMJ Case Rep. 2012 Aug 24;2012:bcr2012006768. PubMed 22922932
Footnotes
1. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem. 2014 Jul;29(3):269-278. PubMed 24966474
2. Lowe D, Sanvictores T, Zubair M, John S. Alkaline Phosphatase. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. 2023 Oct 29. PubMed 29083622
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 001637 | Alk Phos Isoenzymes | 24332-9 | 001107 | Alkaline Phosphatase | IU/L | 6768-6 |
| 001637 | Alk Phos Isoenzymes | 24332-9 | 001638 | Liver Fraction %: | % | 15015-1 |
| 001637 | Alk Phos Isoenzymes | 24332-9 | 001639 | Liver Fraction IU/L: | IU/L | 1779-8 |
| 001637 | Alk Phos Isoenzymes | 24332-9 | 001640 | Bone Fraction %: | % | 15013-6 |
| 001637 | Alk Phos Isoenzymes | 24332-9 | 001641 | Bone Fraction IU/L: | IU/L | 1777-2 |
| 001637 | Alk Phos Isoenzymes | 24332-9 | 001642 | Intestinal Frac.%: | % | 15014-4 |
| 001637 | Alk Phos Isoenzymes | 24332-9 | 001643 | IntestinalFrac.IU/L: | IU/L | 1778-0 |
| Order Code | 001637 | |||||
| Order Code Name | Alk Phos Isoenzymes | |||||
| Order Loinc | 24332-9 | |||||
| Result Code | 001107 | |||||
| Result Code Name | Alkaline Phosphatase | |||||
| UofM | IU/L | |||||
| Result LOINC | 6768-6 | |||||
| Order Code | 001637 | |||||
| Order Code Name | Alk Phos Isoenzymes | |||||
| Order Loinc | 24332-9 | |||||
| Result Code | 001638 | |||||
| Result Code Name | Liver Fraction %: | |||||
| UofM | % | |||||
| Result LOINC | 15015-1 | |||||
| Order Code | 001637 | |||||
| Order Code Name | Alk Phos Isoenzymes | |||||
| Order Loinc | 24332-9 | |||||
| Result Code | 001639 | |||||
| Result Code Name | Liver Fraction IU/L: | |||||
| UofM | IU/L | |||||
| Result LOINC | 1779-8 | |||||
| Order Code | 001637 | |||||
| Order Code Name | Alk Phos Isoenzymes | |||||
| Order Loinc | 24332-9 | |||||
| Result Code | 001640 | |||||
| Result Code Name | Bone Fraction %: | |||||
| UofM | % | |||||
| Result LOINC | 15013-6 | |||||
| Order Code | 001637 | |||||
| Order Code Name | Alk Phos Isoenzymes | |||||
| Order Loinc | 24332-9 | |||||
| Result Code | 001641 | |||||
| Result Code Name | Bone Fraction IU/L: | |||||
| UofM | IU/L | |||||
| Result LOINC | 1777-2 | |||||
| Order Code | 001637 | |||||
| Order Code Name | Alk Phos Isoenzymes | |||||
| Order Loinc | 24332-9 | |||||
| Result Code | 001642 | |||||
| Result Code Name | Intestinal Frac.%: | |||||
| UofM | % | |||||
| Result LOINC | 15014-4 | |||||
| Order Code | 001637 | |||||
| Order Code Name | Alk Phos Isoenzymes | |||||
| Order Loinc | 24332-9 | |||||
| Result Code | 001643 | |||||
| Result Code Name | IntestinalFrac.IU/L: | |||||
| UofM | IU/L | |||||
| Result LOINC | 1778-0 |
| Order Code | Order Name | Result Code | Result Name | UofM | Result LOINC | |
|---|---|---|---|---|---|---|
| Reflex 1 | 001645 | Please Note: | 001645 | Please Note: | N/A | |
| Reflex 1 | ||||||
| Order Code | 001645 | |||||
| Order Name | Please Note: | |||||
| Result Code | 001645 | |||||
| Result Name | Please Note: | |||||
| UofM | ||||||
| Result LOINC | N/A | |||||